price close busi februari
labcorp lead refer laboratori test
compani also oper covanc drug develop
chiltern
laboratori corpor america hold
diagnost tool
labcorp deliv in-lin guid
consist think hold pt
labcorp deliv unev set bar roughli line our/
street expect thesi lh face bridg year hold
expect acceler reimburs pressur pama tune hit
diagnost revenu growth organ diagnost volum flat
slightli due expect share profit loss larg contract
conced labcorp trade trail forward price-to-earnings multipl
howev think pressur compani face merit stock trade discount
recent histori lh expect opportun plenti
also repurchas stock thu think downsid limit reiter hold
rate pt use multipl adj ep
result adj ep narrowli beat our/street estim help
sizabl share buyback rev y/i
light labcorp diagnost rev
line covanc rev came
drag includ divestitur forens lab busi food
solut busi pama impact fewer calendar day impact
advers weather impact organ rev grew y/ contribut
point growth rev off-set divestitur impact fx
impact lh repurchas stock
guid lh initi revenue growth guid prior
adj ep guid flat prior
midpoint guid assum declin core lh diagnost unit
prior midpoint growth covanc in-lin
prior covanc revenu expect full-year guidanc
rang model lh expect dx organ volum flat slightli
y/i due one-tim impact chang certain manag care contract
network lh guid plan activ
deploy acquisit share buyback
 buyback key compon lh repurchas stock
lh author new share buy-back author lh indic
light year activ expect featur increas smaller
tuck-in deal lh activ discuss number health system believ
industri awar financi impact pama risen
expect flat y/i growth alreadi lower guid
part due lower expect direct-to-consum genet test custom
lh expect rel flat y/i growth lh would
elabor suspect may upgrad migrat
technolog enabl greater health insight patient reduc test
discount heavi tv ad spend least vs prior year posit
note lh indic saw improv hospit referr trend decemb
bear watch
model initi estim discuss model updat page
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
laboratori corpor america hold
eye covanc drive growth lh look covanc drive total compani
revenu growth guid declin revenu diagnost segment
lh deliv book-to-bil new standard exit
backlog expect convert revenu next
month lh indic covanc support fda-approv new drug
includ approv orphan drug approv biolog
covanc revenu expect segment guid
continu view demand cro servic robust may mark upsid
model updat new estim move in-lin lh commentari
lower revenu growth y/i prior assum
diagnost covanc revenu growth trim adj ep
y/i look total compani revenu growth
y/i prior assum diagnost covanc growth
initi revenu adj ep estim
y/i
diagnost tool
laboratori corpor america hold
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
laboratori corpor america hold
diagnost tool
laboratori corpor america hold
